Developments in asthma incidence and prevalence in Alberta between 1995 and 2015.
Alberta
Asthma
Epidemiology
Incidence
Prevalence
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
07
2020
accepted:
26
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
Asthma is a chronic respiratory disease characterized by reversible bronchoconstriction and airway inflammation. According to Statistics Canada in 2014, 8.1% of Canadians aged 12 and older reported having asthma diagnosed by a health care professional. Therefore, in 2014 there were an estimated 274,661 persons with asthma in Alberta. Most epidemiological studies estimate prevalence and incidence using survey-based data, which has limitations. The Ontario Asthma Surveillance Information System (OASIS) group has developed and validated an algorithm for epidemiologic asthma studies using provincial health databases. In Alberta, there are some studies using provincial databases, but most are restricted to emergency department visits and do not represent the entire asthma population. Using the validated asthma definition for epidemiologic studies, we performed an analysis of the Alberta Health administrative databases to investigate and report province-wide asthma prevalence, incidence and mortality in Alberta from 1995 to 2015. Data from administrative databases, provided by Alberta Health, was analyzed to determine age and sex specific prevalence, incidence and mortality of the asthma population. The population cohort was all individuals residing in the province of Alberta, ages 0 to 99 from 1995-2015. Kendall's Tau coefficient test was used to ascertain whether the observed trends were statistically significant. Between 1995 and 2015, the age-standardized incidence of asthma decreased by more than 50% in both males and females. Prevalence, however, increased threefold over the 20 years (for both genders) from 3.9 to 12.3% (Tau = 1.00, p < 0.0001) in females and from 3.5 to 11.6% (Tau = 1.00, p < 0.0001) in males. Thus, in 2015 there were 496,927 people with asthma in Alberta. All-cause mortality in the asthma population decreased over time, in both females (Tau = - 0.71, p < 0.0001) and males (Tau = - 0.69, p = 0.0001). For the last several years, all-cause mortality was higher in those with asthma. There were ~ 7 deaths/1000 in the population with asthma versus ~ 5 deaths/1000 in those without asthma. The incidence of asthma decreased in both females and males while prevalence continued to increase, although at a slower rate than previously. All-cause mortality in asthma patients was higher than in those without asthma, but both decreased over time.
Sections du résumé
BACKGROUND
BACKGROUND
Asthma is a chronic respiratory disease characterized by reversible bronchoconstriction and airway inflammation. According to Statistics Canada in 2014, 8.1% of Canadians aged 12 and older reported having asthma diagnosed by a health care professional. Therefore, in 2014 there were an estimated 274,661 persons with asthma in Alberta. Most epidemiological studies estimate prevalence and incidence using survey-based data, which has limitations. The Ontario Asthma Surveillance Information System (OASIS) group has developed and validated an algorithm for epidemiologic asthma studies using provincial health databases. In Alberta, there are some studies using provincial databases, but most are restricted to emergency department visits and do not represent the entire asthma population. Using the validated asthma definition for epidemiologic studies, we performed an analysis of the Alberta Health administrative databases to investigate and report province-wide asthma prevalence, incidence and mortality in Alberta from 1995 to 2015.
METHODS
METHODS
Data from administrative databases, provided by Alberta Health, was analyzed to determine age and sex specific prevalence, incidence and mortality of the asthma population. The population cohort was all individuals residing in the province of Alberta, ages 0 to 99 from 1995-2015. Kendall's Tau coefficient test was used to ascertain whether the observed trends were statistically significant.
RESULTS
RESULTS
Between 1995 and 2015, the age-standardized incidence of asthma decreased by more than 50% in both males and females. Prevalence, however, increased threefold over the 20 years (for both genders) from 3.9 to 12.3% (Tau = 1.00, p < 0.0001) in females and from 3.5 to 11.6% (Tau = 1.00, p < 0.0001) in males. Thus, in 2015 there were 496,927 people with asthma in Alberta. All-cause mortality in the asthma population decreased over time, in both females (Tau = - 0.71, p < 0.0001) and males (Tau = - 0.69, p = 0.0001). For the last several years, all-cause mortality was higher in those with asthma. There were ~ 7 deaths/1000 in the population with asthma versus ~ 5 deaths/1000 in those without asthma.
CONCLUSIONS
CONCLUSIONS
The incidence of asthma decreased in both females and males while prevalence continued to increase, although at a slower rate than previously. All-cause mortality in asthma patients was higher than in those without asthma, but both decreased over time.
Identifiants
pubmed: 33061999
doi: 10.1186/s13223-020-00485-3
pii: 485
pmc: PMC7547457
doi:
Types de publication
Journal Article
Langues
eng
Pagination
87Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Am J Respir Crit Care Med. 2010 Feb 15;181(4):337-43
pubmed: 19926867
Allergy. 2018 Jul;73(7):1479-1488
pubmed: 29461632
Vital Health Stat 3. 2012 Nov;(35):1-58
pubmed: 24252609
BMC Public Health. 2013 Mar 21;13:254
pubmed: 23517452
Acad Emerg Med. 2015 Aug;22(8):942-9
pubmed: 26194859
Eur Respir J. 2004 Feb;23(2):281-6
pubmed: 14979504
Can Respir J. 2001 May-Jun;8(3):139-46
pubmed: 11420589
Am J Epidemiol. 2010 Sep 15;172(6):728-36
pubmed: 20716702
Pediatr Allergy Immunol. 2006 Feb;17(1):69-76
pubmed: 16426258
J Allergy Clin Immunol. 1990 Jun;85(6):1098-111
pubmed: 2355155
BMC Fam Pract. 2015 Feb 14;16:19
pubmed: 25886504
Can Respir J. 2002 Nov-Dec;9(6):407-12
pubmed: 12522486
CJEM. 2010 Jul;12(4):339-46
pubmed: 20650027
Ann Allergy Asthma Immunol. 2004 Mar;92(3):313-8
pubmed: 15049394
Chest. 2009 Jan;135(1):57-65
pubmed: 18689586
Chest. 2012 May;141(5):1190-1196
pubmed: 22030804
Chronic Dis Can. 2009;30(1):20-8
pubmed: 20031085
Curr Opin Pulm Med. 2005 Jan;11(1):79-84
pubmed: 15591893
Pediatr Pulmonol. 2010 Oct;45(10):985-92
pubmed: 20632409
Respir Med. 2018 Sep;142:29-35
pubmed: 30170798
Respir Med. 2020 Apr - May;165:105919
pubmed: 32174450
Ann Am Thorac Soc. 2014 Oct;11(8):1210-7
pubmed: 25166217
BMJ. 2004 Feb 14;328(7436):386-7
pubmed: 14962876
Allergy Asthma Clin Immunol. 2006 Mar 15;2(1):24-38
pubmed: 20529217
Can Respir J. 2009 Nov-Dec;16(6):183-8
pubmed: 20011725
JAMA. 2017 Jan 17;317(3):269-279
pubmed: 28114551